Treace Medical Concepts (TMCI)
NASDAQ:TMCI
Want to see TMCI full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.28Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed picture: commercial execution and product momentum are clear positives (rapid adoption of new systems, expanding TAM, high gross margins, improved cash balance and reduced cash burn expectations), but near-term financials remain challenged (Q1 revenue down 10%, larger net and EBITDA losses, and ASP/mix headwinds). Management is taking a conservative posture—reaffirming guidance while highlighting the path to lapping mix headwinds in the back half of 2026 and expecting revenue growth to return in Q4. Overall, operational improvements and promising adoption trends offset but do not yet fully overcome the near-term revenue and profitability headwinds, leaving the situation balanced between encouraging commercial traction and ongoing financial pressure.Company Guidance
Product Portfolio Expansion and Commercial Progress
Launched multiple new systems (Nanoplasty, Percuplasty 3D MIS, SpeedMTP) and announced upcoming Lapiplasty Lightning, SpeedTMT, SuperBite screws and SpeedXM. Company says these new offerings more than double accessible market relative to Lapiplasty alone and expand TAM by approximately $300M with SuperBite + SpeedXM commercialization planned in Q3 2026.
Rapid Early Adoption by Surgeon Base
Adoption uptake: ~35% of Lapiplasty surgeon users have incorporated at least one of the three new bunion systems (up from 25% in Q4 2025). Over 3,300 active surgeon customers; ~30% of new surgeons who first used a new bunion system have also used Lapiplasty (early pull-through).
Procedure Volume Momentum
Sustained mid-single-digit procedure volume growth reported in Q1 2026, supporting management's view of accelerating market penetration and utilization of the expanded product portfolio.
Strong Gross Margin Profile
Gross margin remained high at 79.3% in Q1 2026 (very close to prior year 79.7%), and management expects to maintain gross margins in the high-70% range as new products scale.
Improved Cash Position and Reduced Cash Burn
Cash, cash equivalents and marketable securities totaled $51.9M as of March 31, 2026 — up ~$3.5M vs $48.4M at Dec 31, 2025. Management expects ~50% reduction in cash usage for full year 2026 vs 2025 and progress toward cash-flow breakeven.
Reaffirmed FY 2026 Guidance and Discipline
Company reaffirmed previously raised full-year revenue guidance of $202M–$212M (a decline of 5% to 0% vs FY2025) and expects an adjusted EBITDA loss of $4M–$6M for 2026, signaling conservative planning and disciplined investment while prioritizing commercialization.
TMCI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TMCI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2026 | $1.92 | $2.01 | +4.69% |
Feb 27, 2026 | $2.10 | $1.86 | -11.43% |
Nov 06, 2025 | $6.23 | $4.46 | -28.41% |
Aug 07, 2025 | $5.68 | $6.13 | +7.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Treace Medical Concepts (TMCI) report earnings?
Treace Medical Concepts (TMCI) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Treace Medical Concepts (TMCI) earnings time?
Treace Medical Concepts (TMCI) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TMCI EPS forecast?
TMCI EPS forecast for the fiscal quarter 2026 (Q2) is -0.3.